Study on the Safety and Effectiveness of a Biodegradable Patent Foramen Ovale Occluder System

Exclusion Criteria

• •An alternative, clearly identified cause of ischemic stroke or TIA (other than PFO) is determined by the investigator.
• •Large territory cerebral infarction within 4 weeks prior to the planned procedure.
• •Atherosclerotic stenosis (\>50%) of the carotid or vertebral arteries, as confirmed by CT angiography or vascular ultrasound per investigator assessment.
• •Presence of intracardiac thrombus or vegetation as confirmed by echocardiography.
• •Left ventricular ejection fraction (LVEF) \< 35%.
• •Atrial fibrillation or atrial flutter.
• •Left ventricular aneurysm or severe regional wall motion abnormality.
• •Significant valvular stenosis or regurgitation, or history of valvular replacement or repair surgery.
• •Pulmonary hypertension or a PFO constituting a special conduit (e.g., right-to-left shunt due to elevated right heart pressures).
• •Other confirmed causes of right-to-left shunt, such as atrial septal defect (ASD) or pulmonary arteriovenous fistula.
• •Complex PFO anatomy (e.g., multi-tunnel PFO) or PFO associated with an ASD requiring different closure strategy.
• •Thrombus, mass, or vegetation identified at the intended implant site or along the potential delivery pathway.
• •Acute myocardial infarction or unstable angina within 3 months prior to the procedure.
• •Previous implantation of an inferior vena cava filter, PFO closure device, or ASD closure device.
• •Any other condition deemed by the investigator to make the patient unsuitable for PFO device implantation.
• •Concomitant cardiac anomalies requiring surgical correction.
• •Uncontrolled systemic or local infection, or sepsis.
• •Active infection requiring concurrent antibiotic therapy (Patients with transient conditions may be enrolled after completing antibiotic therapy and a subsequent 14-day washout period).
• •Contraindication to antiplatelet or anticoagulant therapy (e.g., major bleeding within 3 months, known retinopathy, history of intracranial hemorrhage, or other significant intracranial pathology).
• •Known hypersensitivity or allergy to tantalum or nickel.
• •Pregnancy, lactation, or women of childbearing potential not using highly effective contraception.
• •Life expectancy less than 1 year due to malignancy or other comorbid disease.
• •Current participation in another investigational drug or device clinical study that has not yet completed its primary endpoint.